Tetanus toxoid‐loaded transfersomes for topical immunization

Topical immunization is a novel immunization strategy by which antigens and adjuvants are applied topically to intact skin to induce potent antibody and cell‐mediated responses. Among various approaches for topical immunization, the vesicular approach is gaining wide attention. Proteineous antigen alone or in combination with conventional bioactive carriers could not penetrate through the intact skin. Hence, specially designed, deformable lipid vesicles called transfersomes were used in this study for the non‐invasive delivery of tetanus toxoid (TT). Transfersomes were prepared and characterized for shape, size, entrapment efficiency and deformability index. Fluorescence microscopy was used to investigate the mechanism of vesicle penetration through the skin. The immune stimulating activity of these vesicles was studied by measuring the serum anti‐tetanus toxoid IgG titre following topical immunization. The immune response was compared with the same dose of alum adsorbed tetanus toxoid (AATT) given intramuscularly, topically administered plain tetanus toxoid solution, and a physical mixture of tetanus toxoid and transfersomes again given topically. The results indicated that the optimal transfersomal formulation had a soya phosphatidylcholine and sodium deoxycholate ratio of 85:15%, w/w. This formulation showed maximum entrapment efficiency (87.34±3.81%) and deformability index (121.5±4.21). An in‐vivo study revealed that topically administered tetanus toxoid‐loaded transfersomes, after secondary immunization, elicited an immune response (anti‐TT‐IgG) comparable with that produced by intramuscular AATT. Fluorescence microscopy revealed the penetration of transfersomes through the skin to deliver the antigen to the immunocompetent Langerhans cells.

[1]  Y. Y. Wang,et al.  Effect of liposomes and niosomes on skin permeation of enoxacin. , 2001, International journal of pharmaceutics.

[2]  P. Wertz,et al.  Elasticity of vesicles assessed by electron spin resonance, electron microscopy and extrusion measurements. , 2001, International journal of pharmaceutics.

[3]  Y. Maa,et al.  Adjuvantation of epidermal powder immunization. , 2001, Vaccine.

[4]  C. Alving,et al.  Transcutaneous immunization: A human vaccine delivery strategy using a patch , 2000, Nature Medicine.

[5]  J. Breul,et al.  New Ultradeformable Drug Carriers for Potential Transdermal Application of Interleukin-2 and Interferon-a Theoretic and Practical Aspects , 2000, World Journal of Surgery.

[6]  C. Valenta,et al.  Evaluation of novel soya-lecithin formulations for dermal use containing ketoprofen as a model drug. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[7]  Andreas G. Schätzlein,et al.  Ultraflexible vesicles, Transfersomes, have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin. , 1998, Biochimica et biophysica acta.

[8]  M. Iwaki,et al.  Mechanism for enhancement effect of lipid disperse system on percutaneous absorption : Part II , 1997 .

[9]  A. Schätzlein,et al.  TRANSDERMAL DRUG CARRIERS - BASIC PROPERTIES, OPTIMIZATION AND TRANSFER EFFICIENCY IN THE CASE OF EPICUTANEOUSLY APPLIED PEPTIDES , 1995 .

[10]  N. Weiner,et al.  Liposomes as carriers for topical and transdermal delivery. , 1994, Journal of pharmaceutical sciences.

[11]  G. Cevc,et al.  Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration force. , 1992, Biochimica et biophysica acta.

[12]  T. Kupper Immune and inflammatory processes in cutaneous tissues. Mechanisms and speculations. , 1990, The Journal of clinical investigation.

[13]  P. Bergstresser,et al.  Antigen processing and presentation by epidermal Langerhans cells. Induction of immunity or unresponsiveness. , 1990, Dermatologic clinics.

[14]  N. Weiner,et al.  Topical delivery of liposomally encapsulated interferon evaluated in a cutaneous herpes guinea pig model , 1989, Antimicrobial Agents and Chemotherapy.

[15]  R. Warner,et al.  Electron probe analysis of human skin: determination of the water concentration profile. , 1988, The Journal of investigative dermatology.

[16]  P. Das,et al.  The skin immune system (SIS): distribution and immunophenotype of lymphocyte subpopulations in normal human skin. , 1987, The Journal of investigative dermatology.

[17]  W. Silvers,et al.  Distribution of ATPase‐positive Langerhans cells in normal adult human skin , 1985, The British journal of dermatology.

[18]  A. Florence,et al.  The preparation and properties of niosomes—non‐ionic surfactant vesicles , 1985, The Journal of pharmacy and pharmacology.

[19]  H. Kiwada,et al.  Tissue distribution and pharmacokinetic evaluation of the targeting efficiency of synthetic alkyl glycoside vesicles. , 1985, Chemical & pharmaceutical bulletin.

[20]  R. Steinman,et al.  Murine epidermal Langerhans cells mature into potent immunostimulatory dendritic cells in vitro , 1985, The Journal of experimental medicine.

[21]  R. Handjani-Vila,et al.  Dispersions of lamellar phases of non‐ionic lipids in cosmetic products , 1979, International journal of cosmetic science.

[22]  J. White,et al.  Rapid separation of low molecular weight solutes from liposomes without dilution. , 1978, Analytical biochemistry.

[23]  Sanyog Jain,et al.  Topical immunization: Mechanistic insight and novel delivery systems , 2004 .

[24]  Myron M. Levine,et al.  Can needle-free administration of vaccines become the norm in global immunization? , 2003, Nature Medicine.

[25]  L. Simonsen,et al.  Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. , 1999, Bulletin of the World Health Organization.

[26]  G. Cevc,et al.  Transdermal immunisation with an integral membrane component, gap junction protein, by means of ultradeformable drug carriers, transfersomes. , 1998, Vaccine.

[27]  M. Udey Cadherins and Langerhans cell immunobiology. , 1997, Clinical and experimental immunology.

[28]  T. Kissel,et al.  Parameters affecting the immunogenicity of microencapsulated tetanus toxoid. , 1992, Vaccine.